Exploring New Treatment Options for Cancer Patients

Syndax is developing entinostat and SNDX-6352 in multiple cancer indications. See below for further details.
 

  • Entinostat

    Entinostat as Immunotherapy

    ENCORE 601 / KEYNOTE 142NCT02437136
    Collaboration with Merck

    A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination With Pembrolizumab in Patients With Non-small Cell Lung Cancer, With Expansion Cohorts in Patients With Non-small Cell Lung Cancer and Melanoma.


    ENCORE 602NCT02708680
    Collaboration with Genentech

    A Randomized, Placebo-controlled, Double-blind Phase 2 Study of Atezolizumab With or Without Entinostat in Patients with Metastatic Triple Negative Breast Cancer, with a Phase 1b Lead in Phase.


    ENCORE 603NCT02915523
    Collaboration with Merck KGaA and Pfizer

    A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-in


    Entinostat in HR+ Breast Cancer

    E2112NCT02115282
    Sponsored by NCI/ECOG-ACRIN Cancer Research Group

    A Randomized Phase 3 Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor Positive Advanced Breast Cancer.

    See all our Collaborations

  • SNDX-6352

    SNDX-6352-0001

    Phase 1, Double-Blind, Randomized, Placebo-controlled Trial in Healthy Volunteers to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamice of Escalating Single and Multiple Doses of SNDX-6352 or Placebo Administered by Intravenous (I.V.) Infusion